Illumina, Inc. (ILMN)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
$218.22-1.55%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
Warn: Primary pillar under pressure — Operating margin near 23.4% in 2026: FY26 guidance 23.4% vs target ~23.4%.
Illumina grows revenue about 6.6% a year with raised 2026 revenue guidance near $4.57B. Profit margins improve to about 23.4% in 2026, supporting operating income growth. The company generates strong free cash flow, rising from $208M to $251M in recent quarters. Share buybacks of $1.5B show disciplined capital use.
Growth could slow if integration of SomaLogic falters or if clinical demand weakens. Profit margins may compress if costs rise or competition intensifies. Share price is already high, so any earnings miss could pressure the stock.
The market prices in about 7% revenue growth and expects continued margin improvement. The stock trades roughly 20% above our valuation model's level, reflecting optimism. Our view aligns with consensus on growth but is cautious on valuation stretch.
Breaks if: Repurchase program execution stalls or is canceled
Continue executing the Board-authorized $1.5 billion share repurchase program to return capital to shareholders.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This is a long-term thesis on a company with a mixed management track record and volatile earnings. The current state reflects strong recent financial performance but highlights concerns about cash flow and high valuation compared to peers.
The market appears to have priced in a stretched valuation, suggesting that expectations are relatively high. There is a moderate expectations gap, indicating that investors may be anticipating continued strong performance.
Management is focused on improving operating income and margins, with recent results showing progress in these areas. However, cash flow metrics have declined, which could pose risks to future performance.
The thesis hinges on maintaining strong sector momentum, particularly if leading companies in the healthcare space continue to perform well. Additionally, any negative guidance or economic downturn could significantly impact ILMN's credibility and stock performance.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports a positive outlook. The integration of the SomaLogic acquisition enhances growth potential. There are no new threats impacting the thesis at this time.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 2 of last 2 quarters. The Board authorized an additional $1.5 billion share repurchase program in 2026-Q1. No specific repurchase amounts reported in financials, but the authorization was reiterated and remains active. The trajectory is consistent with management's stated capital allocation focus.
“Based on this performance, we are increasing our revenue and earnings guidance for the year.”
“On April 28, 2026, our Board of Directors authorized an additional $1.5 billion in share repurchases.”
Breaks if: Free cash flow falls below $230M quarterly
Improve cash flow generation through operational efficiency and disciplined capital expenditures.
Stated as a priority in 3 of last 3 quarters. Cash from operations declined from $321M in 2025-Q4 to $201M in 2026-Q2, and free cash flow declined from $267M to $162M over the same period. Despite the stated priority, cash flow metrics show a declining trajectory in the most recent quarters.
“Cash flow provided by operations was $201 million; free cash flow was $162 million.”
“Cash flow provided by operations was $289 million; free cash flow was $251 million.”
“Cash flow provided by operations was $321 million; free cash flow was $267 million.”
Breaks if: Operating margin falls below 22.5% in FY26
Focus on growing operating income and maintaining or improving operating margins through operational efficiency and revenue growth.
Stated as a priority in 3 of last 3 quarters. GAAP operating margin improved from 17.4% in 2025-Q4 to 21.1% in 2026-Q2, while non-GAAP operating margin guidance for 2026 is 23.4%-23.6%, slightly up from 23.1% in 2025. Operating income rose from $202M in 2025-Q4 to $245M in 2026-Q2. The trajectory shows delivering progress on margin improvement and operating income growth.
“GAAP operating margin of 21.1% and non-GAAP operating margin of 22.5%.”
“GAAP operating margin of 19.2% and non-GAAP operating margin of 21.9%.”
“GAAP operating margin of 17.4% and non-GAAP operating margin of 23.7%.”
Breaks if: YoY revenue growth falls below 6% in FY26
Successfully integrate SomaLogic and expand Illumina's multiomics capabilities and product offerings.
Stated as a priority in 3 of last 3 quarters. The acquisition of SomaLogic was completed by 2025-Q4, expanding the multiomics portfolio. Management highlights ongoing expansion of multiomics capabilities and strong demand for NovaSeq X. The trajectory shows progress in integration and portfolio expansion, though no specific revenue or margin impact is quantified.
“Demand for NovaSeq X remains high as we expand our workflow and multiomics capabilities.”
“Illumina delivered a strong start to 2026, reflecting strength of the Illumina ecosystem and progress against our strategy.”
“Completed the acquisition of SomaLogic, expanding Illumina's multiomics portfolio.”
Focus on growing operating income and maintaining or improving operating margins through operational efficiency and revenue growth.
Stated as a priority in 3 of last 3 quarters. GAAP operating margin improved from 17.4% in 2025-Q4 to 21.1% in 2026-Q2, while non-GAAP operating margin guidance for 2026 is 23.4%-23.6%, slightly up from 23.1% in 2025. Operating income rose from $202M in 2025-Q4 to $245M in 2026-Q2. The trajectory shows delivering progress on margin improvement and operating income growth.
“GAAP operating margin of 21.1% and non-GAAP operating margin of 22.5%.”
Overall, ILMN's performance in the next few years will depend on its ability to execute on its priorities while navigating sector dynamics and economic conditions. Not investment advice.
“GAAP operating margin of 19.2% and non-GAAP operating margin of 21.9%.”
“GAAP operating margin of 17.4% and non-GAAP operating margin of 23.7%.”